Safety and tolerability of IgPro10 in Japanese primary immunodeficiency patients: a registrational study

Autor: Kimio Morita, Tomohiro Morio, Kozo Yasui, Amgad Shebl, Kenji Gotoh, Hidenori Ohnishi, Jutta Hofmann, John-Philip Lawo, Mikhail Rojavin, Tomoyuki Imagawa

Publikováno v: International Journal of Hematology. 113:921-929

Studies investigating the safety of IgPro10 (Privigen®, CSL Behring, King of Prussia, PA, USA) in Japanese patients with primary immunodeficiency (PID) are lacking. This study evaluated safety and tolerability of IgPro10 in Japanese patients with PI

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d906988d6c04d57bcb00a93e7064c2a
https://doi.org/10.1007/s12185-021-03106-w

Anti-A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital-based cohort study

Autor: Toby L. Simon, Alphonse Hubsch, Amgad Shebl, Christopher Wallenhorst, Ami Patel, Carlos Martinez

Publikováno v: Transfusion

BACKGROUND Intravenous immunoglobulins (IVIG) are derived from large human plasma pools. IVIG‐associated hemolytic anemia (HA) is a known class effect, likely attributed to dose‐dependent passive transfer of anti‐A/B isoagglutinins. Two isoaggl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ad3a88c0b4c3f992c9f18dc722f455a
https://pubmed.ncbi.nlm.nih.gov/32488887

Hemolysis related to intravenous immunoglobulins is dependent on the presence of anti-blood group A and B antibodies and individual susceptibility

Autor: Alphonse Hubsch, Abdulgabar Salama, Stefano Fontana, Orell Mielke, Vesselina Goranova-Marinova, Sandra Wymann, Billie L. Durn, Martin O. Spycher, John P. Lawo, Amgad Shebl

Publikováno v: Transfusion. 57:2629-2638

BACKGROUND Patients treated with intravenous immunoglobulins (IVIG) rarely experience symptomatic hemolysis. Although anti-A and anti-B isoagglutinins from the product are involved in most cases, the actual mechanisms triggering hemolysis are unclear

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f7e75242fe10184069364ce48c801e57
https://doi.org/10.1111/trf.14289

Measurement of isoagglutinins in immunoglobulins for intravenous application by flow cytometry

Autor: Amgad Shebl, Dominik Stadler, Marc Bürzle, Nicole Spiegl, A. Adriano Marques, Thomas Roten, Lukas Martig, Alphonse Hubsch

Publikováno v: Analytical biochemistry. 591

Isoagglutinins present in intravenous immunoglobulin (IVIG) products have been linked to haemolysis. Therefore, accurately assessing isoagglutinin content in IVIG products is important. The standard European Pharmacopoeia (Ph.Eur.) direct assay is li

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b6903c9271f0ed200f03a88f27a88b4
https://pubmed.ncbi.nlm.nih.gov/31821802

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study

Autor: Michael Schroeter, Amgad Shebl, Leslie Roberts, Takuya Ohkubo, M. Chatzopoulos, Nan van Geloven, Robert D. Henderson, Catharina G. Faber, R. Talab, K. George, A. Kutschenko, E. Chi-Ho Lai, M. Bednar, Inna Rubanovits, Claudia Sommer, J. Oechtering, M. Tomiyama, Hans-Peter Hartung, Mari Auranen, G. Le Masson, Konrad Rejdak, Marina Grandis, Eroboghene E. Ubogu, Senda Ajroud-Driss, Tim Hagenacker, Lisa D. Hobson-Webb, Masayuki Baba, Khema Sharma, Miriam Freimer, Kazumasa Yokoyama, U. Chyrchel-Paszkiewicz, Karissa L. Gable, P. Van Damme, J. Zschuentzsch, I. N. van Schaik, S. Benitez, K. Nishiyama, J. Demeestere, Daniele Cazzato, F. Bethke, R. Carne, Gen Sobue, C. Marquez Infante, Norman Latov, David Walk, B. Murinson, Katrin Gross-Paju, Helmar C. Lehmann, M. Antonia, Ginna Gonzalez, M. Zibetti, Anne-Cécile Wielanek-Bachelet, Vera Bril, Stefania Morino, Mika Saarela, S. Mumfrey, Said R. Beydoun, Takanori Yokota, Maria Salvado, John T. Kissel, C. D'Amour, Ericka Simpson, D. Aufauvre, P. MacDonald, Orell Mielke, David R. Cornblath, Masahiro Iijima, Janneke G. J. Hoeijmakers, Nora A. Visser, Takashi Kanda, K. Kanai, Jeffrey A. Allen, Richard A. Lewis, Anne D. Sperfeld, J. Sussova, D. Mueller, A. Algom, Fabian Klostermann, I. Melamed, David Yarnitsky, J. Haas, Josep Gamez, A Schenone, P. Kunc, Ingemar S. J. Merkies, C. Trebst, F. Ciccocioppo, Ralf Gold, Vivian E. Drory, H. Onoue, Stefan Blum, P. Berlit, S. Muley, Tsugio Akutsu, T. Kalous, Michael P. Lunn, Alessandro Testori, Dale J. Lange, Giuseppe Lauria, D. Liebetanz, A. Jaspert-Grehl, Giovanni Antonini, Masahiro Mori, S. Larue, John-Philip Lawo, C. Goerlitz, H. Johl, M. Kawai, Nicolette C. Notermans, U. Sorro, R. Yoon, Daniela M. Menichella, T. Lavin, Billie L. Durn, J. Morrow, Richard J. Barohn, Dario Cocito, T. Rao, Martin Stangel, Satoshi Kuwabara, Jean Pouget, Emilien Delmont, David Gosal, Alexander Shtilbans, Sandro Sorbi, Florian Then Bergh, J. Schmidt, Shahram Attarian, Pierre Clavelou, Andreas Meisel, Sabrina Matà, Russell L. Chin, Mazen M. Dimachkie, Juliane Klehmet, K. Ohyama, Martin Vališ, Filip Eftimov, Shafeeq Ladha, A. Sabet, P. Baum, Claude Desnuelle, Kenichi Kaida, D. Kramer, Olaf Hoffmann, C. Casanovas Pons, A. Di Muzio, Ivo N. van Schaik, Toomas Toomsoo

Publikováno v: Journal of the peripheral nervous system, 24(1), 72-79. Wiley-Blackwell
Digital.CSIC. Repositorio Institucional del CSIC
instname
Journal of the Peripheral Nervous System, 24(1), 72. Wiley-Blackwell
Journal of the Peripheral Nervous System

PATH study group.
In patients with chronic inflammatory demyelinating polyneuropathy (CIDP), intravenous immunoglobulin (IVIG) is recommended to be periodically reduced to assess the need for ongoing therapy. However, little is known about the e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7039eb5a61ad1011b5914f9a690d3c9c
https://pure.amc.nl/en/publications/restabilization-treatment-after-intravenous-immunoglobulin-withdrawal-in-chronic-inflammatory-demyelinating-polyneuropathy-results-from-the-prerandomization-phase-of-the-polyneuropathy-and-treatment-with-hizentra-study(a3597aa6-7290-41d2-9849-99a91b4daf0e).html